Compare iShares Core Growth Allocation ETF (AOR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Revvity Inc — how do they compare? iShares Core Growth Allocation ETF trades at $70.09, while Revvity Inc trades at $116.27 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares Core Growth Allocation ETF pays none. Which is the better fit depends on your goals.
| AOR | RVTY | |
|---|---|---|
52-Week High | $70.12 | $117.75 |
52-Week Low | $62.26 | $82.26 |
Market Cap | — | $12.91B |
Sector | — | Technology |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, an iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% today. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF maintains a fixed 60/40 stock/bond allocation and rebalances semiannually with a low 0.20% fee. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
The ETF offers diversified exposure but faces risks from equity-bond correlation shifts and competition from pure equity funds. Analyst sentiment is mixed, balancing its simplicity against historical lagging returns. Key catalysts include fee waivers until December 2026 and semiannual rebalancing, but investors should weigh its conservative allocation against growth objectives.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
